{"id":812,"date":"2021-02-05T06:20:48","date_gmt":"2021-02-05T06:20:48","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=812"},"modified":"2021-02-05T06:20:48","modified_gmt":"2021-02-05T06:20:48","slug":"03-feb-2021-sofosbuvir-added-to-the-standard-of-care-sof-accelerated-time-to-the-clinical-response","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/03-feb-2021-sofosbuvir-added-to-the-standard-of-care-sof-accelerated-time-to-the-clinical-response\/","title":{"rendered":"(03 Feb 2021) Sofosbuvir-added to the standard of care, SOF accelerated time to the clinical response"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p>Efficacy and safety of sofosbuvir\/ ledipasvir in treatment of patients with COVID-19; A randomized clinical trial<\/p>\n<p>https:\/\/doi.org\/10.23750\/abm.v91i4.10877<\/p>\n<p class=\"\">IRCT: 20100228003449N29- Clinical response occurred in 91.46% of patients. Although rates of clinical response were comparable between the groups but it occurred faster in the SOF\/LDP group than the control group (2 vs. 4 days respectively, P= 0.02). Supportive cares were provided in the medical wards for most patients but 17.07% of patients were transferred to ICU during the hospitalization course. However, durations of hospital and ICU stay were comparable between the groups. 14&#8211;day mortality rate was 7.14% and 7.5% in the SOF\/ LDP and control groups respectively. No adverse effects leading to drug discontinuation occurred. Gastrointestinal events (nausea, vomiting and diarrhea) were the most common side effects (15.85%). Added to the standard of care, SOF\/LDP accelerated time to the clinical response. However, rate of clinical response, duration of hospital and ICU stay and 14-day mortality were not different. No significant adverse event was detected. More randomized clinical trials with larger sample sizes are needed to confirm the efficacy and safety of SOF\/LDP in the treatment of COVID-19.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Efficacy and safety of sofosbuvir\/ ledipasvir in treatment of patients with COVID-19; A randomized clinical trial https:\/\/doi.org\/10.23750\/abm.v91i4.10877 IRCT: 20100228003449N29- Clinical response occurred in 91.46% of patients. Although rates of clinical response were comparable between the groups but it occurred faster&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/03-feb-2021-sofosbuvir-added-to-the-standard-of-care-sof-accelerated-time-to-the-clinical-response\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(03 Feb 2021) Sofosbuvir-added to the standard of care, SOF accelerated time to the clinical response&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[6,4,95],"tags":[103],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/812"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=812"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/812\/revisions"}],"predecessor-version":[{"id":813,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/812\/revisions\/813"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=812"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=812"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=812"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}